Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyporus polysaccharide (PPS) is a bioactive compound extracted from the medicinal fungus Polyporus umbellatus and related species. It is primarily composed of high-molecular-weight polysaccharides and has demonstrated a range of pharmacological activities including immunomodulatory, anticancer, antioxidant, anti-inflammatory, antifibrotic, and hepatoprotective effects. Mechanistically, PPS exerts its effects by modulating immune responses (stimulating natural killer cells, T cells, B cells, and macrophages), inhibiting tumor cell proliferation (notably in bladder cancer), suppressing myofibroblast differentiation via inhibition of the TGF-β/Smad2/3 pathway in pulmonary fibrosis models[1][5], inducing autophagy in cancer cells through macrophage regulation[2][6], and enhancing cytokine production such as NO, IL-6 and TNF-α by activated macrophages[5]. In China, both capsule and injectable forms have been approved for clinical use—most notably for hepatitis B treatment—and are also used as adjuncts in cancer therapy[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyporus polysaccharide.